

Freedom of Information Request	FOI 21-168	5 <sup>th</sup> May 2021
--------------------------------	------------	--------------------------

**Q1. In the last three months, how many patients have been treated by your haemophilia centre with the following products?**

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra
- Jivi
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

Zero (0) patients have been treated with these products by the Health Board in the last three months. Haemophilia patients are managed by Cardiff and Vale University Health Board; please contact Cardiff and Vale UHB for further information

**Q2. In the last three months, how many patients were treated with the following products for mild Haemophilia A ONLY?**

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra
- Jivi
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

Zero (0) patients have been treated with these products by the Health Board in the last three months.

**Q3. For patients treated with Hemlibra in the last three months, please provide**

- The number of haemophilia A patients with inhibitors
- The number of mild haemophilia A patients with inhibitors

Not applicable.

**Q4. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.**

Ten (10) patients with mild haemophilia are registered with the Health Board.